Twist Bioscience (NASDAQ:TWST) Given New $33.00 Price Target at Robert W. Baird

Twist Bioscience (NASDAQ:TWSTGet Rating) had its price target decreased by Robert W. Baird from $56.00 to $33.00 in a research note issued to investors on Monday, The Fly reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other research firms have also recently issued reports on TWST. SVB Leerink cut their target price on shares of Twist Bioscience from $45.00 to $30.00 and set a market perform rating for the company in a research note on Monday. Barclays dropped their price objective on shares of Twist Bioscience from $45.00 to $43.00 and set an overweight rating for the company in a research note on Monday.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $25.61 on Monday. The firm has a 50-day moving average of $33.24 and a 200-day moving average of $36.99. The stock has a market cap of $1.44 billion, a PE ratio of -6.35 and a beta of 1.15. Twist Bioscience has a 52-week low of $23.90 and a 52-week high of $105.37.

Insiders Place Their Bets

In other Twist Bioscience news, SVP Paula Green sold 8,514 shares of Twist Bioscience stock in a transaction dated Friday, September 16th. The shares were sold at an average price of $37.43, for a total value of $318,679.02. Following the completion of the sale, the senior vice president now owns 14,199 shares in the company, valued at approximately $531,468.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 9,211 shares of company stock worth $341,371 in the last quarter. 3.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently bought and sold shares of the company. Nicholas Investment Partners LP increased its holdings in Twist Bioscience by 69.6% in the 1st quarter. Nicholas Investment Partners LP now owns 279,864 shares of the company’s stock valued at $13,820,000 after buying an additional 114,813 shares during the period. Sit Investment Associates Inc. increased its holdings in Twist Bioscience by 5.5% in the 1st quarter. Sit Investment Associates Inc. now owns 24,075 shares of the company’s stock valued at $1,189,000 after buying an additional 1,250 shares during the period. Amalgamated Bank increased its holdings in Twist Bioscience by 4.4% in the 1st quarter. Amalgamated Bank now owns 8,677 shares of the company’s stock valued at $428,000 after buying an additional 368 shares during the period. Autonomy Capital Jersey L.P. bought a new position in Twist Bioscience in the 1st quarter valued at about $83,000. Finally, Stanley Laman Group Ltd. bought a new stake in shares of Twist Bioscience during the 2nd quarter valued at approximately $1,210,000.

Twist Bioscience Company Profile

(Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Articles

The Fly logo

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.